When a routine blood test at a local charity event flagged unusual results, retired engineer Keith Davies had no idea it would lead to a prostate cancer diagnosis three years later. Today, he’s not only cancer-free but back to running, walking football and urging men over 45 to act now. His message is clear: early detection changes everything.
Keith Davies, 74, had a pivotal blood test in 2020 that revealed elevated levels of prostate-specific antigen (PSA), a protein produced by the prostate gland. While it wasn’t until 2023 that further testing confirmed prostate cancer, that early signal enabled medical teams to closely monitor his condition. Treated by the Royal Wolverhampton NHS Trust (RWT), Davies underwent hormone therapy and a 20-session course of radiotherapy. Just one month after treatment, he was back to running 5k, walking daily, and playing walking football.
His treatment began immediately upon referral to oncology in December 2023, where he received his first hormone tablet and, shortly after, began regular injections to reduce testosterone levels—a hormone that fuels prostate cancer. His final hormone injection was administered in October, and since then, his PSA levels have become undetectable.
Now, almost fully recovered, Davies says he feels 90–95% back to his former self. He credits not only the skilled NHS staff but also the guidance from Prostate Cancer UK, which helped him navigate his diagnosis and treatment. His advice to others is straightforward and urgent: men over 45 should get tested. It’s a simple blood test that could make all the difference.
Prostate cancer remains one of the most common cancers among men, but early detection significantly improves treatment outcomes. With non-invasive blood testing and access to MRI scans when necessary, more men like Keith Davies are beating the odds.
EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development of new medicines for cancer, neurology, heart disease and infectious diseases.
